Table 1:
Patient characteristics at transplantation.
| ADPKD complete n = 193 | ADPKD matched-pair n = 189 | Control matched-pair n = 189 | P value | |
|---|---|---|---|---|
| Recipient age (years), mean ± SD | 55.1 ± 10.2 | 55.1 ± 10.1 | 55.2 ± 10.2 | .924 |
| Waiting time (months), mean ± SD | 47.9 ± 42.1 | 48.2 ± 42.4 | 50.1 ± 37.0 | .643 |
| Female recipient, n (%) | 81 (42.0) | 80 (42.3) | 80 (42.3) | |
| Recipient HbA1c, mean ± SD | 5.4 ± 0.7 | 5.6 ± 0.8 | 5.7 ± 0.9 | .254 |
| Recipient BMI (kg/m2), mean ± SD | 26.0 ± 3.9 | 26.0 ± 3.9 | 26.2 ± 4.9 | .661 |
| Recipient CCI score, mean ± SD | 3.6 ± 1.3 | 3.6 ± 1.3 | 4.0 ± 1.8 | .069 |
| Unilateral nephrectomy before Tx, n (%) | 61 (31.6) | 61 (32.3) | 12 (6.3) | <.001 |
| Bilateral nephrectomy before Tx, n (%) | 22 (11.4) | 22 (11.6) | 9 (4.8) | .015 |
| Underlying cause of chronic kidney disease | ||||
| Diabetic nephropathy, n (%) | 18 (9.5) | |||
| Vascular nephropathy, n (%) | 19 (10.1) | |||
| Primary glomerulopathy, n (%) | 70 (37.0) | |||
| Systemic disease, n (%) | 8 (4.2) | |||
| Hereditary kidney disease, n (%) | 10 (5.3) | |||
| Obstructive nephropathy/chronic pyelonephritis, n (%) | 26 (13.8) | |||
| Miscellaneous, n (%) | 13 (6.9) | |||
| Undetermined, n (%) | 25 (13.2) | |||
| vPRA %, mean ± SD | 6.5 ± 21.5 | 6.6 ± 21.7 | 11.3 ± 26.5 | .061 |
| Donor age (years), mean ± SD | 54.1 ± 13.9 | 54.2 ± 14.0 | 53.8 ± 14.8 | .787 |
| Donor eGFRcr (ml/min/1.73 m2), mean ± SD | 83.4 ± 24.6 | 83.6 ± 24.7 | 84.5 ± 24.7 | .723 |
| Living donor, n (%) | 68 (35.2) | 65 (34.4) | 65 (34.4) | |
| Preemptive Tx, n (%) | 23 (11.9) | 22 (11.6) | 12 (6.4) | .072 |
| AB0 compatible Tx, n (%) | 177 (91.7) | 174 (92.1) | 183 (96.8) | .073 |
| Steroids, n (%) | 193 (100.0) | 189 (100.0) | 189 (100.0) | |
| Basiliximab, n (%) | 183 (94.8) | 179 (94.7) | 177 (93.7) | .660 |
| Cyclosporine A, n (%) | 85 (44.0) | 83 (43.9) | 83 (43.9) | |
| Tacrolimus, n (%) | 104 (53.9) | 102 (54.0) | 102 (54.0) | |
| Everolimus, n (%) | 3 (1.6) | 3 (1.6) | 2 (1.1) | .653 |
| Belatacept, n (%) | 1 (0.5) | 1 (0.5) | 3 (1.6) | .315 |
| Mycophenolate, n (%) | 179 (92.7) | 175 (92.6) | 182 (96.3) | .116 |
| Fingolimod, n (%) | 2 (1.0) | 2 (1.1) | 1 (0.5) | .562 |
| Sotrastaurin, n (%) | 12 (6.2) | 12 (6.3) | 5 (2.7) | .082 |
Immunosuppression refers to the initial treatment after Tx.
Note: in the control group one patient concomitantly received cyclosporine A and everolimus.
Abbreviations: ADPKD, polycystic kidney disease; BMI, body mass index; CCI, Charlson Comorbidity Index; eGFRcr, creatinine-based estimated glomerular filtration rate; SD, standard deviation; Tx, transplantation; vPRA, virtual panel reactive antibodies (Eurotransplant Reference Laboratory, HLA database version 4).
Chi-square test for categorical variables, Wilcoxon signed-rank-test for continuously distributed variables.